Summit Therapeutics Inc.

Key metrics

Financial performance

Net profit margin compressed from -163.6% to -11174.8% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (532 filings)

Recent press releases

• HARMONi-7 Clinical Study2026-04-30
• Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 20262026-04-30

  _Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China_

• Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 20262026-03-27

  _Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study_

• Summit Therapeutics to Present at Upcoming Investor Conferences2026-02-26

  Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences:

• Presentation(opens in new window)2026-02-23

Similar companies

The largest companies sharing Summit Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).